Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT02258009 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Visual Impairment Due to Diabetic Macular Edema

Interventions

DRUG: Ranibizumab
DRUG: Aflibercept

Sponsor

Novartis Pharmaceuticals